Correlation Between Egetis Therapeutics and Ziccum AB

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Egetis Therapeutics and Ziccum AB at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Egetis Therapeutics and Ziccum AB into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Egetis Therapeutics AB and Ziccum AB, you can compare the effects of market volatilities on Egetis Therapeutics and Ziccum AB and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Egetis Therapeutics with a short position of Ziccum AB. Check out your portfolio center. Please also check ongoing floating volatility patterns of Egetis Therapeutics and Ziccum AB.

Diversification Opportunities for Egetis Therapeutics and Ziccum AB

-0.84
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Egetis and Ziccum is -0.84. Overlapping area represents the amount of risk that can be diversified away by holding Egetis Therapeutics AB and Ziccum AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Ziccum AB and Egetis Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Egetis Therapeutics AB are associated (or correlated) with Ziccum AB. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Ziccum AB has no effect on the direction of Egetis Therapeutics i.e., Egetis Therapeutics and Ziccum AB go up and down completely randomly.

Pair Corralation between Egetis Therapeutics and Ziccum AB

Assuming the 90 days trading horizon Egetis Therapeutics AB is expected to generate 0.75 times more return on investment than Ziccum AB. However, Egetis Therapeutics AB is 1.34 times less risky than Ziccum AB. It trades about 0.02 of its potential returns per unit of risk. Ziccum AB is currently generating about -0.04 per unit of risk. If you would invest  604.00  in Egetis Therapeutics AB on November 2, 2024 and sell it today you would earn a total of  12.00  from holding Egetis Therapeutics AB or generate 1.99% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Egetis Therapeutics AB  vs.  Ziccum AB

 Performance 
       Timeline  
Egetis Therapeutics 

Risk-Adjusted Performance

14 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Egetis Therapeutics AB are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Egetis Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.
Ziccum AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Ziccum AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Egetis Therapeutics and Ziccum AB Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Egetis Therapeutics and Ziccum AB

The main advantage of trading using opposite Egetis Therapeutics and Ziccum AB positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Egetis Therapeutics position performs unexpectedly, Ziccum AB can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ziccum AB will offset losses from the drop in Ziccum AB's long position.
The idea behind Egetis Therapeutics AB and Ziccum AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Complementary Tools

Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets